Harrinton’s venture was incorporated in Delaware in May 2025,under the name Preventive Medicine PBC. As a public-benefit corporation, it is organized to put its public mission above profits. “If our research shows [heritable genome editing] cannot be done safely, that conclusion is equally valuable to the scientific community and society,” Harrington wrote in his post.
Harrington is a cofounder of Mammoth Biosciences, a gene-editing company pursuing drugs for adults, and remains a board member there.
In recent months, Preventive has sought endorsements from leading figures in genome editing, but according to its post, it had secured only one—from Paula Amato, a fertility doctor at Oregon Health Sciences University, who said she had agreed to act as an advisor to the company.
Amato is a member of a US team that has researched embryo editing in the country since 2017, and she has promoted the technology as a way to increase IVF success. That could be the case if editing could correct abnormal embryos, making more available for use in trying to create a pregnancy.
It remains unclear where Preventive’s funding is coming from. Harrington said the $30 million was gathered from “private funders who share our commitment to pursuing this research responsibly.” But he declined to identify those investors other than SciFounders, a venture firm he runs with his personal and business partner Matt Krisiloff, the CEO of the biotech company Conception, which aims to create human eggs from stem cells.
That’s yet another technology that could change reproduction, if it works. Krisiloff is listed as a member of Preventive’s founding team.
The idea of edited babies has received growing attention from figures in the cryptocurrency business. These include Brian Armstrong, the billionaire founder of Coinbase, who has held a series of off-the-record dinners to discuss the technology (which Harrington attended). Armstrong previously argued that the “time is right” for a startup venture in the area.
